Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
この資料は、米国アムジェン社が2023年10月6日に発表したニュースリリースの日本語抄訳であり、報道関係者
各位の利便性のために提供するものです。この資料の正式言語は英語であり、その内容及び解釈については英語を
優先します。詳細は
https://www.amgen.com/newsroom をご参照下さい。
カリフォルニア州サウザンドオークス（2023年10月6日）– アムジェン社（ナスダック：AMGN）は本日、Horizon Therapeutics plc（以下、Horizon社）の株式を1株あたり現金116.50ドルで取得し、買収を完了したことをお知らせいたします。これは約278億ドルの株式価値に相当します。
アムジェンの会長 兼 最高経営責任者である Robert A. Bradwayは次のように述べています。 「私たちは本日、Horizon社の従業員をアムジェン社に迎え入れ、重篤な疾患に苦しむ世界中の患者さんのために協働を開始する、エキサイティングな節目を迎えました。当社の中核事業には力強い勢いがあり、Horizon社のポートフォリオが加わることで、当社はさらに幅広い疾患領域のリーダーとしての地位を確立します」
アムジェン社は、この買収には次に挙げる説得力のある戦略的および財務的根拠があると考えています。
アムジェン社は、第3四半期の決算発表時に、最新の2023年度ガイダンスを発表する予定です。
アムジェン社について
アムジェン社（Amgen
Inc.）は、革新的な治療薬の発見、開発、製造、提供を通じて、重篤な疾患に苦しむ患者さんのために生物学の可能性を切り拓くことに取り組んでいます。このアプローチは、疾患の複雑性を解明し、人体の生物学上の基本を理解するために、先進的なヒト遺伝学などの手法を活用することから始まります。
アムジェン社は、アンメット・メディカル・ニーズが大きい領域に焦点を絞り、専門知識を活用して、医療効果を向上させ、人々の生活に画期的な改善をもたらすソリューションを追求しています。1980年に創業したバイオテクノロジーのパイオニアであるアムジェン社は、世界最大の独立バイオテクノロジー企業の一社に成長し、世界中の何百万という患者さんに貢献しており、革新的な可能性が期待されるパイプラインを開発しています。
アムジェン社はダウ・ジョーンズ工業株価平均を構成する30社のうちの一社であり、ナスダック100指数にも含まれています。2023年には、Newsweekの「America’s Greatest Workplaces」、USA Todayの「America’s Climate Leaders」、TIMEの「World’s Best Companies」のうちの一社に選ばれました。
詳細については Amgen.com をご覧になるか、X（旧Twitter）、LinkedIn、Instagram、TikTok 及び YouTube をフォローしてください。
Horizon社について
Horizon社は、希少疾患、自己免疫性疾患および重度炎症性疾患に悩む人々のニーズに応える医薬品の発見、開発、および商業化に注力しているグローバルバイオテクノロジー企業です。Horizon社の製品群および開発中製品のゴールは、患者さんに専門的かつ臨床的に有意な治療法を提供することにあります。我々は、人々の生活を変えるには、開発技術と思いやりの両方が重要だと考えます。
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the Horizon Therapeutics plc acquisition (including the prospective performance and outlook of Horizon’s business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such acquisition or integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
注意事項
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン社（カリフォルニア州サウザンドオークス）
Jessica Akopyan, 805-440-5721 （メディア向け）
Justin Claeys, 805-313-9775（投資家向け）
アムジェン株式会社（東京）
コーポレート・アフェアーズ
mailto:jpto-mediarelationsgroup@amgen.com